ReviewCancers2022
Non-Operative Management of Patients with Rectal Cancer: Lessons Learnt from the OPRA Trial.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06940388 (Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer: An Open-label Randomized Controlled Phase II Study (The TOTAL Trial)
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Shared decision-making in radiotherapy for rectal cancer - A systematic review.Technical innovations & patient support in radiation oncology · 2026Review
- Article
- Strategies to reduce intestinal toxicity in neoadjuvant management of locally advanced rectal cancer.Discover oncology · 2025Review
- Stool shed cell transcriptomics mirrors tumor biology and enables colorectal cancer diagnosis.Scientific reports · 2025Article
- Watch and wait in locally advanced rectal cancer: Evolution, current evidence, and future directions.World journal of gastrointestinal surgery · 2025Review
- The role of radiotherapy in the management of metastatic rectal cancer: A narrative review on the opportunities for non-operative management and organ preservation.Clinical and translational radiation oncology · 2025Review
- A case report of recurrent endometrial cancer invading the rectum and bladder with concurrent primary rectal cancer treated with total neoadjuvant therapy and pelvic exenteration.Journal of surgical case reports · 2025Article
- Controversies and Perspectives in the Current Management of Patients with Locally Advanced Rectal Cancer-A Systematic Review.Life (Basel, Switzerland) · 2025Review
- Impact of Neoadjuvant Treatment on Target Expression in Rectal Cancer for Near-Infrared Tumor Imaging.Cancers · 2025Article
- Organ Function Preservation in Locally Advanced Low Rectal Cancer Through Total Neoadjuvant Therapy: A Case Report and Literature Review.Cancer management and research · 2025Article
- Watch and wait in rectal cancer patients with residual mucin on magnetic resonance imaging following neoadjuvant therapy.Journal of the National Cancer Institute · 2024Article
- Colorectal cancer: Recent advances in management and treatment.World journal of clinical oncology · 2024Review
- Article
- The Role of Predictive and Prognostic MRI-Based Biomarkers in the Era of Total Neoadjuvant Treatment in Rectal Cancer.Cancers · 2024Review
- Colon cancer survival in the elderly without curative surgery.Annals of the Royal College of Surgeons of England · 2024Article
- Outcomes of Locally Advanced Rectal Cancer Patients Following Complete Clinical Response After Neoadjuvant Treatment.Cureus · 2024Article
- MR-linac based radiation therapy in gastrointestinal cancers: a narrative review.Journal of gastrointestinal oncology · 2024Review
- Non-operative management of rectal cancer: Highlighting the controversies.World journal of gastrointestinal surgery · 2024Article
- Synchronous Gastric and Rectal Adenocarcinoma With Complete Response After Total Neoadjuvant Therapy: A Case Report.Cureus · 2024Article
- Higher rate of pathologic complete response in patients with early-onset locally advanced rectal cancer.ESMO gastrointestinal oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Over the past decade, the management of locally advanced rectal cancer (LARC) has progressively become more complex. The introduction of total neoadjuvant treatment (TNT) has increased the rates of both clinical and pathological complete response, resulting in excellent long-term oncological outcomes. As a result, non-operative management (NOM) of LARC patients with a clinical complete response (cCR) after neoadjuvant therapy has gained acceptance as a potential treatment option in selected cases. NOM is based on replacement of surgical resection with safe and active surveillance. However, the identification of appropriate candidates for a NOM strategy without compromising oncologic safety is currently challenging due to the lack of an objective standardization. NOM should be part of the treatment plan discussion with LARC patients, considering the increasing rates of cCR, patient preference, quality of life, expectations, and the potential avoidance of surgical morbidity. The recently published OPRA trial showed that organ preservation is achievable in half of rectal cancer patients treated with TNT, and that chemoradiotherapy followed by consolidation chemotherapy may an appropriate strategy to maximize cCR rates. Ongoing trials are investigating optimal algorithms of TNT delivery to further expand the pool of patients who may benefit from NOM of LARC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.